AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04511104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care rehabilitation
Study NCT04511104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care rehabilitation
Study NCT02327689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine plus adefovir dipivoxil
Description: emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
Study NCT00777491 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Induction QD radiation therapy
Description: Once daily (QD) on days (1-5,8-12,15-19,22-26). For the first 10 treatment days, 2 Gy is delivered to the pelvis. Then, 2 Gy is delivered to the bladder for the next 4 treatment days, followed by 2 Gy to the bladder tumor volume for the remaining 6 treatment days. The bladder tumor volume receives a total of 40 Gy.
Study NCT00777491 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidation BID radiation therapy
Description: Twice daily (BID) for 8 days on days 1,2,3,4,5,8,9,10 of consolidation. 1.5 Gy per fraction for a total of 24 Gy delivered to the pelvis.
Study NCT00777491 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidation QD radiation therapy
Description: Once daily (QD) pelvic radiation therapy for 12 days on days 1-5,8-12,15-16 of consolidation. 2 Gy per fraction for a total of 24 Gy delivered to the pelvis.
Study NCT00777491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: consolidation gemcitabine
Description: 27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15 of consolidation.
Study NCT00777491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: consolidation 5-fluorouracil
Description: 400 mg/m\^2 administered as a 24-hour infusion on days 1, 2, 3 and 8, 9, 10 of consolidation.
Study NCT00777491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: consolidation cisplatin
Description: 15 mg/m\^2 administered as a sixty-minute infusion on days 1, 2, 8, 9 of consolidation.
Study NCT00777491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical cystectomy
Description: Operable patients who have a pT1 or worse tumor response on re-evaluation following initial transurethral resection and induction chemoradiotherapy will have a radical cystectomy 3-8 weeks following the post-induction response evaluation.
Study NCT00777491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-Induction Chemoradiotherapy Endoscopic Response Evaluation
Description: Urine cytology, cystoscopy, tumor site transurethral biopsy, and bimanual examination after biopsy.
Study NCT00777491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant gemcitabine
Description: 1000 mg/m\^2 administered intravenously over 30-60 minutes (preferably 30 minutes) on days 1 and 8 of each 21-day cycle for four cycles.
Study NCT03250221 — intervention group
Intervention type: DEVICE
Intervention: barbed sutures
Description: Use of the barbed sutures for robotic or laparoscopic myomectomy
Study NCT03250221 — intervention group
Intervention type: DEVICE
Intervention: Vicryl@ suture
Description: Use of Vicryl@ suture for robotic or laparoscopic myomectomy
Study NCT04376463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Aminoacid
Description: It is an experimental design, controlled with 8 months of supplementation combined with exercise and washout 2 months, totalling 10 month intervention.
Study NCT00777491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant cisplatin
Description: 70 mg/m\^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
Study NCT04371731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care4todayheart failure platform
Description: Platform allowing patients to enter information about their health at home, namely weight and BP and medications
Study NCT00767156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omega7 Sea Buckthorn Oil Cream
Description: The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
Study NCT00767156 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Base cream
Description: The subjects use the base cream on the face, twice per day
Study NCT00767156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SBA24 Sea Buckthorn Oil Capsule
Description: The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
Study NCT00767156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SBA24 Sea Buckthorn Oil Capsule
Description: Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
Study NCT03364933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary intensivist and nurses
Description: Primary intensivist will have no active role in the daily management of patients. The primary intensivist should facilitate decision-making, be a liaison between the patient/family and PICU team, and be a resource of information for all. Responsibilities of primary intensivist:~* Weekly check-in with and availability to patient/family~* Attendance at family meetings~* Availability to PICU team~Primary nurses will be a team of up to 7 ICU nurses who will provide as much of the bedside care as possible. Responsibilities of primary nurses:~* Maintain a primary nurse binder (paper format) for on-going communication about the patient among the team members; it will be their discretion what is information is communicated.~* The Primary Nurse or delegate will be involved in all team/family meetings and will be expected/given an opportunity to speak during these meetings.
Study NCT04567823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smoothie with microalgae
Description: Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
Study NCT04567823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Smoothie with microalgae
Description: Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
Study NCT03063242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.
Study NCT02654704 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pneumococcal Vaccination
Description: The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
Study NCT02334332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational brochure
Study NCT02334332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Receive standard post-operative care
Study NCT03038087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSE Device
Description: The SENSE device transmits a low power tailored electro-magnetic pulse across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~1. A molded plastic headpiece containing the antenna array, and~2. A processing control unit.~The SENSE device will be placed on the subject within 15 minutes of a baseline head CT, or as soon as practicable. The SENSE device will be set to scan every 10 minutes until the device is removed after completion of the SENSE measurement corresponding to the 72 hour CT scan. The investigator will be blinded to the data collected from the SENSE device.
Study NCT05932498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip surgery
Description: Ultrasound-guided PENG block was administered to patients undergoing hip surgery intraoperatively.~OR~Ultrasound-guided QL block was administered to patients undergoing hip surgery intraoperatively.
Study NCT03029117 — intervention group
Intervention type: PROCEDURE
Intervention: correction of rheumatic valve lesions
Study NCT00864799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
Study NCT02812771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinaconazole
Description: Solution
Study NCT06355830 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Orthoptic assessment (Outcome measure)
Description: The protocol image assessment is non-invasive and includes retinal imaging by Color Fundus photography (CFP), Spectral Domain Optical Coherence Tomography (SD-OCT), OCT-Angiography (OCT-A) using Spectralis OCT, with OCT Angiography Module (Heidelberg Eng. GmbH, Germany).
Study NCT01029392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2000iu once a day
Study NCT00869661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 or 48 weeks
Study NCT05932498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip surgery
Description: Ultrasound-guided PENG block was administered to patients undergoing hip surgery intraoperatively.~OR~Ultrasound-guided QL block was administered to patients undergoing hip surgery intraoperatively.
Study NCT03063242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be drawn at baseline and during each subsequent visit
Study NCT05040048 — intervention group
Intervention type: OTHER
Intervention: Clinical, biological and imaging assessment
Study NCT04042519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Agilent 1290 Infinity LC system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection.
Description: We used the Agilent 1290 Infinity LC system mass spectrometer to analyze and detect metabolite peaks of patients according to retention time and mass/charge ratio after preliminary experiments and derivatization.
Study NCT04042519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Routine blood test
Description: Blood routine test results include CRP, PCT, white blood cell count, red blood cell count, neutrophil percentage, eosinophil, basophil, et al.
Study NCT00434278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase alfa
Description: 2.5 mg inhalation dose twice daily for 14±2 days
Study NCT00434278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2.5 mg inhalation dose twice daily for 14±2 days
Study NCT03095508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angal S, topical spray [Menthol]
Description: 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
Study NCT01051661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)
Description: Intramuscular injection, one or two doses
Study NCT03095508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTI-ANGIN® FORMULA, topical metered spray
Description: 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution
Study NCT00611832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple P Media Series -- Standard Information-Only version
Description: 10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
Study NCT01051661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
Description: Intramuscular injection, two doses
Study NCT01051661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection, one dose
Study NCT02259803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/amlodipine fixed-dose combination (FDC) tablet
Study NCT02259803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02259803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study NCT04728425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous immunoglobulin (SCIG)
Description: 20% subcutaneous immunoglobulin
Study NCT00611832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P Media Series -- Enhanced Behavior Activation version
Description: 10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
Study NCT02777879 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
Study NCT03569683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External bevel gingivectomy
Description: External bevel gingivectomy will be performed on 30 patients wherein the suprabony pockets will be eliminated with the help of a Bard parker blade no 15. The incision would be given 1mm apical to the pockets which would be marked by a Crane and Kaplan pocket marker, then the incision would be given and the tissue would be removed with the help of kirkland and orbans knives and the gingiva would be shaped. After the surgical procedure the patients would be treated either with the Diode laser(Group A), Hyaluronic acid gel (Group B), or Herbal gel(Group C).
Study NCT03569683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser Biostimulation
Description: After gingivectomy, laser irradiation will be done using bio-stimulation tip in the anterior sextants of the mouth. (Group A)
Study NCT04728425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)
Description: 10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin
Study NCT00869661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 48 weeks
Study NCT03569683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Gengigel) topical application.
Description: After gingivectomy, Hyaluronic acid gel(Gengigel) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group B)
Study NCT03569683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal gel (Hiora SG) topical application
Description: After gingivectomy, Herbal gel(Hiora SG) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group C)
Study NCT02860260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Study NCT02860260 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Study NCT02860260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral MRI
Study NCT02860260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cerebral MRI
Study NCT01511250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
Study NCT02284893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: administered orally once daily
Study NCT02284893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: administered orally once daily
Study NCT02284893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: administered orally once daily
Study NCT02284893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with Saxagliptin
Description: administered orally once daily
Study NCT02284893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with Dapagliflozin
Description: administered orally once daily
Study NCT02284893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with Sitagliptin
Description: administered orally once daily
Study NCT04440774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIK low dose
Description: A single dose of 5x10\^9 vp ChAdOx1 Chik
Study NCT04440774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIK mid dose
Description: A single dose of 2.5x10\^10 vp ChAdOx1 Chik
Study NCT04440774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIK high dose
Description: A single dose of 5x10\^10 vp ChAdOx1 Chik
Study NCT04440774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZIKA low dose
Description: A single dose of 5x10\^9 vp ChAdOx1 Zika
Study NCT04440774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZIKA mid dose
Description: A single dose of 2.5x10\^10 vp ChAdOx1 Zika
Study NCT04440774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZIKA high dose
Description: A single dose of 5x10\^10 vp ChAdOx1 Zika
Study NCT04440774 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: A single dose of isotonic saline solution (0.9%)
Study NCT01061788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479, Everolimus, Panitumumab
Description: Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~1. 3-6 subjects, Study drug administered per dose level~2. 3-6 subjects, Study drug administered per dose level~   Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~   Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3. 3-6 subjects, Study drug administered per dose level~4. 3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level
Study NCT02686944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intuvax (ilixadencel)
Description: Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection
Study NCT06489509 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive End Expiratory Pressure 5 H2O
Description: Positive End Expiratory Pressure 5 H2O from CPAP apparatus
Study NCT06489509 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive End Expiratory Pressure 10 H2O
Description: Positive End Expiratory Pressure 5 H2O from CPAP apparatus
Study NCT03935347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03935347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT00869661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: 1000/1200mg po daily for 48 weeks
Study NCT00869661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 24 or 48 weeks
Study NCT01511250 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
Study NCT04527614 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: qRT-PCR and serology
Description: qRT-PCR and serology
Study NCT00869661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 48 weeks
Study NCT00869661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 micrograms sc weekly for 48 weeks
Study NCT00869661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000mg bid for 24 weeks
Study NCT00869661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 500mg bid for 12 weeks
Study NCT00869661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000mg bid for 8 weeks
Study NCT00869661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000mg bid for 12 weeks
Study NCT00785681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINBACK (Lactic Acid)
Study NCT02518217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Apps
Description: Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.